Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.

Buchan SL, Dou L, Remer M, Booth SG, Dunn SN, Lai C, Semmrich M, Teige I, Mårtensson L, Penfold CA, Chan HTC, Willoughby JE, Mockridge CI, Dahal LN, Cleary KLS, James S, Rogel A, Kannisto P, Jernetz M, Williams EL, Healy E, Verbeek JS, Johnson PWM, Frendéus B, Cragg MS, Glennie MJ, Gray JC, Al-Shamkhani A, Beers SA.

Immunity. 2018 Nov 20;49(5):958-970.e7. doi: 10.1016/j.immuni.2018.09.014. Epub 2018 Nov 13.

PMID:
30446386
2.

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, Glennie MJ, White AL.

Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22.

3.

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.

Turaj AH, Cox KL, Penfold CA, French RR, Mockridge CI, Willoughby JE, Tutt AL, Griffiths J, Johnson PWM, Glennie MJ, Levy R, Cragg MS, Lim SH.

Sci Rep. 2018 Feb 2;8(1):2278. doi: 10.1038/s41598-018-20656-y.

4.

Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.

Larkin SE, Johnston HE, Jackson TR, Jamieson DG, Roumeliotis TI, Mockridge CI, Michael A, Manousopoulou A, Papachristou EK, Brown MD, Clarke NW, Pandha H, Aukim-Hastie CL, Cragg MS, Garbis SD, Townsend PA.

Br J Cancer. 2016 Oct 25;115(9):1078-1086. doi: 10.1038/bjc.2016.291. Epub 2016 Sep 29.

5.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS.

J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28.

6.

Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo.

Tipton TR, Mockridge CI, French RR, Tutt AL, Cragg MS, Beers SA.

Blood. 2015 Dec 10;126(24):2643-5. doi: 10.1182/blood-2015-09-671339. Epub 2015 Oct 22. No abstract available.

PMID:
26492935
7.

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS.

Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.

8.

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

Tipton TR, Roghanian A, Oldham RJ, Carter MJ, Cox KL, Mockridge CI, French RR, Dahal LN, Duriez PJ, Hargreaves PG, Cragg MS, Beers SA.

Blood. 2015 Mar 19;125(12):1901-9. doi: 10.1182/blood-2014-07-588376. Epub 2015 Jan 28.

PMID:
25631769
9.

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

Cancer Cell. 2015 Jan 12;27(1):138-48. doi: 10.1016/j.ccell.2014.11.001. Epub 2014 Dec 11.

10.

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.

Hussain K, Hargreaves CE, Roghanian A, Oldham RJ, Chan HT, Mockridge CI, Chowdhury F, Frendéus B, Harper KS, Strefford JC, Cragg MS, Glennie MJ, Williams AP, French RR.

Blood. 2015 Jan 1;125(1):102-10. doi: 10.1182/blood-2014-08-593061. Epub 2014 Nov 13.

PMID:
25395427
11.

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.

White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K, Williams EL, Booth SG, French RR, Potter EA, Butts C, Al-Shamkhani A, Cragg MS, Verbeek JS, Johnson PW, Glennie MJ, Beers SA.

J Immunol. 2014 Aug 15;193(4):1828-35. doi: 10.4049/jimmunol.1303204. Epub 2014 Jul 14.

12.

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).

Williams EL, Tutt AL, French RR, Chan HT, Lau B, Penfold CA, Mockridge CI, Roghanian A, Cox KL, Verbeek JS, Glennie MJ, Cragg MS.

Eur J Immunol. 2012 Aug;42(8):2109-20. doi: 10.1002/eji.201142302. Epub 2012 Jul 4.

13.

Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.

Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, Cook SJ, Stevenson FK, Packham G.

Blood. 2012 Feb 16;119(7):1726-36. doi: 10.1182/blood-2011-07-367417. Epub 2011 Dec 7.

PMID:
22160382
14.

Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells.

Krysov S, Dias S, Paterson A, Mockridge CI, Potter KN, Smith KA, Ashton-Key M, Stevenson FK, Packham G.

Blood. 2012 Jan 5;119(1):170-9. doi: 10.1182/blood-2011-07-370403. Epub 2011 Nov 15.

PMID:
22086413
15.

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg MS, Glennie MJ.

Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18.

PMID:
21768293
16.

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

J Immunol. 2011 Aug 15;187(4):1754-63. doi: 10.4049/jimmunol.1101135. Epub 2011 Jul 8.

17.

Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo.

Krysov S, Potter KN, Mockridge CI, Coelho V, Wheatley I, Packham G, Stevenson FK.

Blood. 2010 May 27;115(21):4198-205. doi: 10.1182/blood-2009-12-254847. Epub 2010 Mar 17.

PMID:
20237321
18.

The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL.

Forconi F, Potter KN, Wheatley I, Darzentas N, Sozzi E, Stamatopoulos K, Mockridge CI, Packham G, Stevenson FK.

Blood. 2010 Jan 7;115(1):71-7. doi: 10.1182/blood-2009-06-225813. Epub 2009 Nov 3.

PMID:
19887677
19.

Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.

Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK.

Blood. 2007 May 15;109(10):4424-31. Epub 2007 Jan 25.

PMID:
17255355
20.

Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.

Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, Mimura Y, Kimura Y, Sim RB, Inogès S, Rodriguez-Calvillo M, Zabalegui N, de Cerio AL, Potter KN, Mockridge CI, Dwek RA, Bendandi M, Rudd PM, Stevenson FK.

J Biol Chem. 2007 Mar 9;282(10):7405-15. Epub 2006 Dec 29.

21.

Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia.

Potter KN, Mockridge CI, Neville L, Wheatley I, Schenk M, Orchard J, Duncombe AS, Packham G, Stevenson FK.

Clin Cancer Res. 2006 Mar 15;12(6):1672-9.

22.

Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.

McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin F, Bowdish KS.

Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1041-6. Epub 2006 Jan 17.

23.

Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection.

Mockridge CI, Rahman A, Buchan S, Hamblin T, Isenberg DA, Stevenson FK, Potter KN.

Autoimmunity. 2004 Feb;37(1):9-15.

PMID:
15115306
24.

Disturbances in peripheral blood B cell subpopulations in autoimmune patients.

Potter KN, Mockridge CI, Rahman A, Buchan S, Hamblin T, Davidson B, Isenberg DA, Stevenson FK.

Lupus. 2002;11(12):872-7. Review.

PMID:
12529053
25.

Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire.

Potter KN, Orchard J, Critchley E, Mockridge CI, Jose A, Stevenson FK.

Blood. 2003 Apr 15;101(8):3082-4. Epub 2002 Dec 12.

PMID:
12480699
26.

Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing.

Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK.

Blood. 2001 Aug 15;98(4):1174-81.

PMID:
11493467
27.

Sequence analysis of V(4-34)-encoded antibodies from single B cells of two patients with systemic lupus erythematosus (SLE).

Mockridge CI, Chapman CJ, Spellerberg MB, Sheth B, Fleming TP, Isenberg DA, Stevenson FK.

Clin Exp Immunol. 1998 Oct;114(1):129-36.

28.

Phage surface expression for analysis of recognition sites of human autoantibodies: comparison of single chain Fv and Fab.

Chapman CJ, Mockridge CI, Spellerberg MB, Zhu D, Stevenson FK.

Hum Antibodies. 1997;8(3):124-8.

PMID:
9322082
29.
30.
31.

Use of a phage expression system to produce Fabs from human autoanti-DNA antibodies encoded by the VH4-21 gene segment.

Chapman CJ, Mockridge CI, Spellerberg MB, Isenberg DA, Hamblin TJ, Stevenson FK.

Ann N Y Acad Sci. 1995 Sep 29;764:576-9. No abstract available.

PMID:
7486589
32.

Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity.

Chapman CJ, Mockridge CI, Rowe M, Rickinson AB, Stevenson FK.

Blood. 1995 Apr 15;85(8):2176-81.

PMID:
7718888
33.

Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: a possible link between infection and lupus.

Spellerberg MB, Chapman CJ, Mockridge CI, Isenberg DA, Stevenson FK.

Hum Antibodies Hybridomas. 1995;6(2):52-6.

PMID:
7492751
34.

Radioimmunoassayable insulin-like growth factor-I in human breast cyst fluid.

Wang DY, Hamed H, Mockridge CI, Fentiman IS.

Eur J Cancer Clin Oncol. 1989 May;25(5):867-72.

PMID:
2786810
35.

Measurement of human corticosteroid binding globulin by enzyme-linked immunoassay.

Fantl VE, Wang DY, Mockridge CI.

J Steroid Biochem. 1988 Aug;31(2):187-93.

PMID:
3404988
36.

Urinary epidermal growth factor excretion and breast cancer risk.

Wang DY, Mockridge CI, Fantl VE, de Stavola B, Allen DS, Thomas BS, Moore JW, Bulbrook RD, Gravelle IH, Kwa HG, et al.

Eur J Cancer Clin Oncol. 1988 Jun;24(6):1049-53.

PMID:
3261690

Supplemental Content

Loading ...
Support Center